Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Cyclosporine

FDA-approved product (injectable, injection), marketed as Cequa, Cyclosporine, Gengraf and 6 more.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
4 of 4

Chemical structure

Chemical structure of Cyclosporine
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Conjunctivitis
  • Corneal disease
  • Eye disease
  • Immune system disease
  • Inflammation
  • Keratitis
  • Keratoconjunctivitis
  • Psoriasis
  • Rheumatoid arthritis

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Calcineurin inhibitors; Other ophthalmologicals
FDA pharmacologic class
Calcineurin Inhibitor Immunosuppressant FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against E. coli, MRSA, K. pneumoniae and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA61.7% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli53.3% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae56.1% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis50.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Cyclosporine in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Cyclosporine with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Utilization of a Microdevice for Psoriasis and Atopic Dermatitis

    NCT07352566 · start 2026-08-01

    Registered record
    Registry ID
    NCT07352566
    Conditions
    Psoriasis; Atopic Dermatitis
    Interventions
    In situ cutaneous microdevice; Triamcinolone; 5-Fluorouracil; Calcipotriene; Tapinarof; Crisaborole; Tacrolimus; Adalimumab; Etanercept; Certolizumab; Infliximab; Secukinumab; Ixekizumab; Apremilast; Risankizumab; Ustekinumab; Hydroxychloroquine; Methotrexate; Mycophenolate; Azathioprine; Chloroquine; Cyclosporine; Tofacitinib; Deucravacitinib; Dupilumab; Tralokinumab; Guselkumab; Tildrakizumab; Baractinib; Abrocitinib; Upadacitinib; Lebrikizumab; Nemolizumab; Ruxolitinib; Bimekizumab; Roflumilast
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Not yet recruiting
    Start
    2026-08-01
    Completion
    2030-06-01
    Enrolment
    10

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPsoriasis; Atopic Dermatitis
    InterventionIn situ cutaneous microdevice; Triamcinolone; 5-Fluorouracil; Calcipotriene +32 more
    PhasePhase 4
    Registry statusNot yet recruiting

  • IFN-α in Relapse Prevention.

    NCT07449286 · start 2026-03-01

    Registered record
    Registry ID
    NCT07449286
    Conditions
    Acute Myeloid Leukemia; Myelodysplastic Syndromes
    Interventions
    IFN-α
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Not yet recruiting
    Start
    2026-03-01
    Completion
    2027-06-30
    Enrolment
    100

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcute Myeloid Leukemia; Myelodysplastic Syndromes
    InterventionIFN-α
    PhasePhase 2
    Registry statusNot yet recruiting

  • Letermovir Prophylaxis in Children With EBV-Positive T/NK-Cell Lymphoproliferative Disease and Refractory/Relapsed EBV-Associated Hemophagocytic Lymphohistiocytosis

    NCT07488728 · start 2025-10-01

    Registered record
    Registry ID
    NCT07488728
    Conditions
    EBV-associated T/NK-cell Lymphoproliferative Diseases; Refractory/Relapsed EBV-related Hemophagocytic Lymphohistiocytosis; Letermovir
    Interventions
    Letermovir
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Recruiting
    Start
    2025-10-01
    Completion
    2026-12-31
    Enrolment
    80

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionEBV-associated T/NK-cell Lymphoproliferative Diseases; Refractory/Relapsed EBV-related Hemophagocytic Lymphohistiocytosis; Letermovir
    InterventionLetermovir
    PhaseNot applicable
    Registry statusRecruiting

  • Open Label Trial of Oral Letermovir for CMV Prophylaxis in Thoracic Transplant Recipients

    NCT06066957 · start 2024-04-04

    Registered record
    Registry ID
    NCT06066957
    Conditions
    Cytomegalovirus Infections; Transplant-Related Disorder
    Interventions
    Letermovir 480 MG [Prevymis]
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2024-04-04
    Completion
    2026-08-15
    Enrolment
    80

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCytomegalovirus Infections; Transplant-Related Disorder
    InterventionLetermovir 480 MG [Prevymis]
    PhasePhase 2
    Registry statusRecruiting

  • Efficacy and Safety of Nemolizumab in Subjects With Moderate-to-Severe Atopic Dermatitis With Inadequate Response to or for Whom Cyclosporine A is Not Medically Advisable

    NCT05056779 · start 2023-01

    Registered record
    Registry ID
    NCT05056779
    Conditions
    Moderate-to-severe Atopic Dermatitis
    Interventions
    Nemolizumab; CD14152 placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Withdrawn
    Start
    2023-01
    Completion
    2023-07
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionModerate-to-severe Atopic Dermatitis
    InterventionNemolizumab; CD14152 placebo
    PhasePhase 3
    Registry statusWithdrawn

  • Up-front Hematopoietic Stem Cell Transplantation in Acute Myeloid Leukemia Patients Aged 65-75

    NCT03902665 · start 2019-03-15

    Registered record
    Registry ID
    NCT03902665
    Conditions
    Acute Myeloid Leukemia, Adult
    Interventions
    Up-front allogeneic hematopoietic stem cell transplantation (HSCT)
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2019-03-15
    Completion
    2024-06-30
    Enrolment
    19

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcute Myeloid Leukemia, Adult
    InterventionUp-front allogeneic hematopoietic stem cell transplantation (HSCT)
    PhasePhase 2
    Registry statusCompleted

  • Spanish Academy of Dermatology and Venereology Registry of Atopic Dermatitis Therapy

    NCT05674695 · start 2019-01-01

    Registered record
    Registry ID
    NCT05674695
    Conditions
    Dermatitis, Atopic
    Interventions
    Ciclosporin
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Recruiting
    Start
    2019-01-01
    Completion
    2029-01-01
    Enrolment
    2,500

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDermatitis, Atopic
    InterventionCiclosporin
    PhaseNot recorded
    Registry statusRecruiting

  • A Novel TBI Free Conditioning Protocol for Haploidentical Transplant in Acquired Aplastic Anemia:

    NCT03955601 · start 2018-07-12

    Registered record
    Registry ID
    NCT03955601
    Conditions
    Aplastic Anemia Idiopathic
    Interventions
    Haploidentical HSCT using TBI free regimen, ''ATG'' with ''Post transplant cyclophosphamide''
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Unknown
    Start
    2018-07-12
    Completion
    2021-06-30
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAplastic Anemia Idiopathic
    InterventionHaploidentical HSCT using TBI free regimen, ''ATG'' with ''Post transplant cyclophosphamide''
    PhasePhase 2
    Registry statusUnknown

  • Multicenter Randomized Two-arms Study Evaluating the BK Viral Clearance in Kidney Transplant Recipients With BK Viremia.

    NCT03216967 · start 2018-01-15

    Registered record
    Registry ID
    NCT03216967
    Conditions
    BK Virus Nephropathy After Kidney Transplantation
    Interventions
    everolimus
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2018-01-15
    Completion
    2024-08-01
    Enrolment
    130

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBK Virus Nephropathy After Kidney Transplantation
    Interventioneverolimus
    PhasePhase 4
    Registry statusCompleted

  • Effect of Vitamin C on Collagen Production in Comparison to Hereditary Gingival Fibromatosis: Histopathological Study

    NCT07043985 · start 2018-01-03

    Registered record
    Registry ID
    NCT07043985
    Conditions
    Tissue Modification After Vit c Injection
    Interventions
    biopsy
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2018-01-03
    Completion
    2025-05-06
    Enrolment
    20

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTissue Modification After Vit c Injection
    Interventionbiopsy
    PhaseNot applicable
    Registry statusCompleted

  • Eltrombopag Combined With Cyclosporine as First Line Therapy in Patients With Severe Acquired Aplastic Anemia

    NCT02998645 · start 2017-05-11

    Registered record
    Registry ID
    NCT02998645
    Conditions
    Severe Aplastic Anemia
    Interventions
    eltrombopag; Cyclosporine
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2017-05-11
    Completion
    2022-05-30
    Enrolment
    54

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSevere Aplastic Anemia
    Interventioneltrombopag; Cyclosporine
    PhasePhase 2
    Registry statusCompleted

  • A Controlled Study of Steroids Plus Cyclosporin Therapy for Patients of Idiopathic Membranous Nephropathy

    NCT02173106 · start 2014-06

    Registered record
    Registry ID
    NCT02173106
    Conditions
    Idiopathic Membranous Nephropathy; Proteinuria; Spontaneous Remission; Steroid Nephropathy; Cyclosporin Overdose
    Interventions
    steroid & Cyclosporin
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Unknown
    Start
    2014-06
    Completion
    2016-12
    Enrolment
    180

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionIdiopathic Membranous Nephropathy; Proteinuria; Spontaneous Remission; Steroid Nephropathy +1 more
    Interventionsteroid & Cyclosporin
    PhasePhase 2
    Registry statusUnknown

  • 70% Ethanol for Decontamination of CVL Exposed to Calcineurine Inhibitors Version 1.0, 1/9/2014

    NCT02441075 · start 2014-05

    Registered record
    Registry ID
    NCT02441075
    Conditions
    Hematopoietic Stem Cell Transplant; GVHD
    Interventions
    70% Ethanol
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2014-05
    Completion
    2016-01
    Enrolment
    13

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHematopoietic Stem Cell Transplant; GVHD
    Intervention70% Ethanol
    PhaseNot applicable
    Registry statusCompleted

  • A Pilot Study Comparing the Safety and Efficacy of Everolimus With Other Medicines in Recipients of ECD/DCD Kidneys

    NCT01878786 · start 2013-06

    Registered record
    Registry ID
    NCT01878786
    Conditions
    Delayed Graft Function
    Interventions
    Everolimus; Tacrolimus; Mycophenolate mofetil (MMF/MPA)
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Terminated
    Start
    2013-06
    Completion
    2017-12
    Enrolment
    25

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDelayed Graft Function
    InterventionEverolimus; Tacrolimus; Mycophenolate mofetil (MMF/MPA)
    PhasePhase 2 / Phase 3
    Registry statusTerminated

  • Economic Evaluation of Systemic Treatments for Moderate-to-severe Psoriasis

    NCT01812954 · start 2013-03

    Registered record
    Registry ID
    NCT01812954
    Conditions
    Psoriasis
    Interventions
    Methotrexate; Cyclosporins; fumaric acid; Acitretin; Infliximab; etanercept; Adalimumab; Ustekinumab
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2013-03
    Completion
    2014-06
    Enrolment
    1

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPsoriasis
    InterventionMethotrexate; Cyclosporins; fumaric acid; Acitretin +4 more
    PhaseNot recorded
    Registry statusCompleted